AbbVie announced that its investigational drug etentamig met the dual primary endpoints of objective response rate and progression-free survival in a Phase 3 study for relapsed/refractory multiple myeloma. The results were presented at the 23rd International Myeloma Society Annual Meeting, highlighting significant improvements over standard therapies. AbbVie also showcased other promising treatments in its multiple myeloma portfolio, including trispecific T-cell engager ABBV-2001 and BCL-2 inhibitor surzetoclax. These developments support AbbVie's strategy to address disease complexity and patient needs with innovative therapies.
AbbVie shares trade at USD 263.20 on Pluang as of Sep 17, 2026 19:42 WIB, near their 52-week high of USD 265.97. The stock shows a modest 1-day gain of 0.24%, with a strong buy interest at 86% of order activity. AbbVie’s market cap stands at $463.89 billion, reflecting its significant presence in the health sector.
